Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

neurotech

  • Home
  •  
  • neurotech



  • Most Read
  • Latest Comments
  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

  • Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    • News

  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

  • Pharmaxis welcomes leading medical researcher and healthcare investment guru as Director
    Pharmaxis welcomes leading medical researcher and healthcare investment guru as Director
    • News

  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

    Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome

    About one in 9,000 females in Australia are diagnosed with Rett Syndrome at birth. In the US, about 15,000 girls and women suffer from it, and globally, this number grows to 350,000 females. The significance of its prevalence is nothing compared to its impact. The disorder can have a detrimental effect on the lives of

    Read More
    Public
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

    Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug

    Autism Spectrum Disorder (ASD) affects 1 in 150 Australians. Boys are 4 times more likely to have it than girls, and symptoms are noticeable at around 2-3 years of age. According to the Australian Institute of Health and Welfare, the number of people with ASD in Australia is increasing, providing an impetus for biopharmaceutical company

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.